bluebird bio, Inc. Stock

$4.97

0.00%

Nasdaq, Thu, Jun 12 2025

ISIN

US09609G1004

Symbol

BLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Key metrics

Basic

Market capitalization

$48.7m

Enterprise Value

$129.3m

Net debt

$80.7m

Cash

$78.7m

Shares outstanding

9.8m

Valuation (TTM | estimate)

P/E

- | -

P/S

0.5 | 0.2

EV/Sales

1.2 | 0.6

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-6.9%

Return on Equity

763.4%

ROCE

1,101.0%

ROIC

-145.0%

Debt/Equity

-2.8

Financials (TTM | estimate)

Revenue

$104.0m | $222.3m

EBITDA

$-149.2m | $-126.1m

EBIT

$-210.5m | $-157.1m

Net Income

$-200.0m | $-115.0m

Free Cash Flow

$-230.5m

Growth (TTM | estimate)

Revenue

127.4% | 165.2%

EBITDA

48.3% | 38.9%

EBIT

36.5% | 41.3%

Net Income

34.0% | 52.2%

Free Cash Flow

1.0%

EPS

$-20.5

FCF per Share

$-23.5

Short interest

2.9%

Employees

248

Rev per Employee

$340.0k

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Get Started for Free Today

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a bluebird bio, Inc. forecast:

6x Buy

60%

4x Hold

40%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a bluebird bio, Inc. forecast:

Buy

60%

Hold

40%

Analyst Estimates with Stock Price Targets

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	104 104	127% 127% 100%
- Direct Costs	76 76	35% 35% 73%
Gross Profit	28 28	371% 371% 27%
- Selling and Administrative Expenses	152 152	13% 13% 146%
- Research and Development Expense	87 87	41% 41% 84%
EBITDA	-149 -149	48% 48% -144%
- Depreciation and Amortization	61 61	43% 43% 59%
EBIT (Operating Income) EBIT	-211 -211	36% 36% -203%
Net Profit	-200 -200	34% 34% -192%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

bluebird bio, Inc. Stock News

Neutral

Business Wire

●

9 days ago

bluebird bio Strengthens Leadership Team With New Appointments

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the appointment of Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff, further bolstering its deeply experienced management team. “I am thrilled to welcome Brian, Joanne and Adr...

Neutral

Business Wire

●

about one month ago

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly...

Neutral

Business Wire

●

about one month ago

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share,...

More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Andrew Obenshain
Employees	248
Founded	1992
Website	www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now